Functional inhibition of Oct leads to HNF4α upregulation

Vollmar,Johanna; Kim,Yong Ook; Marquardt,Jens Uwe; Galle,Peter R.; Schuppan,Detlef; Zimmermann,Tim

doi:10.3892/etm.2021.9780

Functional inhibition of Oct leads to HNF4α upregulation

Authors:
- Johanna Vollmar
- Yong Ook Kim
- Jens Uwe Marquardt
- Peter R. Galle
- Detlef Schuppan
- Tim Zimmermann
View Affiliations

Affiliations: Department of Internal Medicine II, Hospital of Worms, D-67550 Worms, Germany, Institute of Translational Immunology, Fibrosis and Metabolism Centre, Johannes Gutenberg‑University Mainz, D-55131 Mainz, Germany, Department of Internal Medicine I, University Hospital Schleswig‑Holstein, D-23538 Lübeck, Germany, 1st Department of Internal Medicine, Gastroenterology and Hepatology, University Medical Centre, Johannes Gutenberg‑University Mainz, D-55131 Mainz, Germany
Published online on: February 11, 2021 https://doi.org/10.3892/etm.2021.9780
Article Number: 349
Copyright: © Vollmar et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Organic cation transporters (human, OCT; mouse, Oct) are responsible for the intracellular uptake and detoxification of a broad spectrum of endogenous and exogenous substrates. The OCT1 gene SLC22A1 (human; mouse, Scl22a1) is transactivated by hepatocyte nuclear factor 4α (human, HNF4α; mouse, Hnf4α). HNF4α is a master regulator of hepatocyte differentiation and is frequently associated with hepatocellular carcinoma (HCC). In addition, the downregulation of HNF4α is associated with enhanced fibrogenesis. Our recent study revealed that hepatocarcinogenesis and fibrosis were enhanced with the loss of Oct3 (gene, Slc22a3). Notably, differences in Hnf4α expression, and in cholestasis and fibrosis were also detected in Oct3‑knockout (FVB.Slc22a3tm10pb, Oct3^‑/‑) mice. To the best of our knowledge, no data exists on an interaction between Oct3 and Hnf4α. We hypothesised that loss of Oct3 may have an impact on Hnf4α expression. In the present study, gene expression analyses were performed in liver tissue from untreated Oct3^‑/‑ and wild type (FVB, WT) mice. C57BL/6, Oct3^‑/‑ and WT mice were treated with pro‑fibrotic carbon tetrachloride (CCl4) or thioacetamide (TAA) for 6 weeks to chemically induce liver fibrosis. Cholestasis‑associated fibrosis was mechanically generated in Oct3^‑/‑ and WT mice by bile duct ligation (BDL). Finally, stably OCT1‑ and OCT3‑transfected tumour cell lines and primary murine hepatocytes were treated with the non‑selective OCT inhibitor quinine and Hnf4α expression was quantified by qPCR and immunofluorescence. The results revealed that Hnf4α is one of the top upstream regulators in Oct3^‑/‑ mice. Hnf4α mRNA expression levels were downregulated in Oct3^‑/‑ mice compared with in WT mice during cholestatic liver damage as well as fibrogenesis. The downregulation of Hnf4α mRNA expression in fibrotic liver tissue was reversible within 4 weeks. In stably OCT1‑ and OCT3‑transfected HepG2 and HuH7 cells, and primary murine hepatocytes, functional inhibition of OCT led to the upregulation of Hnf4α mRNA expression. Hnf4α was revealed to be located in the cytosol of WT hepatocytes, whereas Oct3^‑/‑ hepatocytes exhibited nuclear Hnf4α expression. In conclusion, Hnf4α was downregulated in response to cholestasis and fibrosis, and functional inhibition of Oct may lead to the upregulation of Hnf4α.

View Figures

View References

1	Heise M, Lautem A, Knapstein J, Schattenberg JM, Hoppe-Lotichius M, Foltys D, Weiler N, Zimmermann A, Schad A, Gründemann D, et al: Downregulation of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) in human hepatocellular carcinoma and their prognostic significance. BMC Cancer. 12(109)2012.PubMed/NCBI View Article : Google Scholar
2	Lautem A, Heise M, Gräsel A, Hoppe-Lotichius M, Weiler N, Foltys D, Knapstein J, Schattenberg JM, Schad A, Zimmermann A, et al: Downregulation of organic cation transporter 1 (SLC22A1) is associated with tumor progression and reduced patient survival in human cholangiocellular carcinoma. Int J Oncol. 42:1297–1304. 2013.PubMed/NCBI View Article : Google Scholar
3	Grimm D, Lieb J, Weyer V, Vollmar J, Darstein F, Lautem A, Hoppe-Lotichius M, Koch S, Schad A, Schattenberg JM, et al: Organic Cation Transporter 1 (OCT1) mRNA expression in hepatocellular carcinoma as a biomarker for sorafenib treatment. BMC Cancer. 16(94)2016.PubMed/NCBI View Article : Google Scholar
4	Herraez E, Lozano E, Macias RI, Vaquero J, Bujanda L, Banales JM, Marin JJ and Briz O: Expression of SLC22A1 variants may affect the response of hepatocellular carcinoma and cholangiocarcinoma to sorafenib. Hepatology. 58:1065–1073. 2013.PubMed/NCBI View Article : Google Scholar
5	Vollmar J, Lautem A, Closs E, Schuppan D, Kim YO, Grimm D, Marquardt JU, Fuchs P, Straub BK, Schad A, et al: Loss of organic cation transporter 3 (Oct3) leads to enhanced proliferation and hepatocarcinogenesis. Oncotarget. 8:115667–115680. 2017.PubMed/NCBI View Article : Google Scholar
6	Saborowski M, Kullak-Ublick GA and Eloranta JJ: The human organic cation transporter-1 gene is transactivated by hepatocyte nuclear factor-4alpha. J Pharmacol Exp Ther. 317:778–785. 2006.PubMed/NCBI View Article : Google Scholar
7	Rulcova A, Krausova L, Smutny T, Vrzal R, Dvorak Z, Jover R and Pavek P: Glucocorticoid receptor regulates organic cation transporter 1 (OCT1, SLC22A1) expression via HNF4alpha upregulation in primary human hepatocytes. Pharmacol Rep. 65:1322–1335. 2013.PubMed/NCBI View Article : Google Scholar
8	Parviz F, Matullo C, Garrison WD, Savatski L, Adamson JW, Ning G, Kaestner KH, Rossi JM, Zaret KS and Duncan SA: Hepatocyte nuclear factor 4alpha controls the development of a hepatic epithelium and liver morphogenesis. Nat Genet. 34:292–296. 2003.PubMed/NCBI View Article : Google Scholar
9	Sasaki S, Urabe M, Maeda T, Suzuki J, Irie R, Suzuki M, Tomaru Y, Sakaguchi M, Gonzalez FJ and Inoue Y: Induction of hepatic metabolic functions by a novel variant of hepatocyte nuclear factor 4γ. Mol Cell Biol. 8:e00213–18. 2018.PubMed/NCBI View Article : Google Scholar
10	Ning BF, Ding J, Yin C, Zhong W, Wu K, Zeng X, Yang W, Chen YX, Zhang JP, Zhang X, et al: Hepatocyte nuclear factor 4 alpha suppresses the development of hepatocellular carcinoma. Cancer Res. 70:7640–7651. 2010.PubMed/NCBI View Article : Google Scholar
11	Walesky C, Edwards G, Borude P, Gunewardena S, O'Neil M, Yoo B and Apte U: Hepatocyte nuclear factor 4 alpha deletion promotes diethylnitrosamine-induced hepatocellular carcinoma in rodents. Hepatology. 57:2480–2490. 2013.PubMed/NCBI View Article : Google Scholar
12	Saha SK, Parachoniak CA, Ghanta KS, Fitamant J, Ross KN, Najem MS, Gurumurthy S, Akbay EA, Sia D, Cornella H, et al: Mutant IDH inhibits HNF-4alpha to block hepatocyte differentiation and promote biliary cancer. Nature. 513:110–114. 2014.PubMed/NCBI View Article : Google Scholar
13	Wu N, Zhang YL, Wang HT, Li DW, Dai HJ, Zhang QQ, Zhang J, Ma Y, Xia Q, Bian JM and Hang HL: Overexpression of hepatocyte nuclear factor 4α in human mesenchymal stem cells suppresses hepatocellular carcinoma development through Wnt/β-catenin signaling pathway downregulation. Cancer Biol Ther. 17:558–565. 2016.PubMed/NCBI View Article : Google Scholar
14	Yue HY, Yin C, Hou JL, Zeng X, Chen YX, Zhong W, Hu PF, Deng X, Tan YX, Zhang JP, et al: Hepatocyte nuclear factor 4alpha attenuates hepatic fibrosis in rats. Gut. 59:236–246. 2010.PubMed/NCBI View Article : Google Scholar
15	Fan TT, Hu PF, Wang J, Wei J, Zhang Q, Ning BF, Yin C, Zhang X, Xie WF, Chen YX and Shi B: Regression effect of hepatocyte nuclear factor 4alpha on liver cirrhosis in rats. J Dig Dis. 14:318–327. 2013.PubMed/NCBI View Article : Google Scholar
16	Park MR, Wong MS, Araúzo-Bravo MJ, Lee H, Nam D, Park SY, Seo HD, Lee SM, Zeilhofer HF, Zaehres H, et al: Oct4 and Hnf4α-induced hepatic stem cells ameliorate chronic liver injury in liver fibrosis model. PLoS One. 14(e0221085)2019.PubMed/NCBI View Article : Google Scholar
17	Zwart R, Verhaagh S, Buitelaar M, Popp-Snijders C and Barlow DP: Impaired activity of the extraneuronal monoamine transporter system known as uptake-2 in Orct3/Slc22a3-deficient mice. Mol Cell Biol. 21:4188–4196. 2001.PubMed/NCBI View Article : Google Scholar
18	Vollmar J, Kim YO, Marquardt JU, Becker D, Galle PR, Schuppan D and Zimmermann T: Deletion of organic cation transporter Oct3 promotes hepatic fibrosis via upregulation of TGFβ. Am J Physiol Gastrointest Liver Physiol. 317:G195–G202. 2019.PubMed/NCBI View Article : Google Scholar
19	Jonker JW and Schinkel AH: Pharmacological and physiological functions of the polyspecific organic cation transporters: OCT1, 2, and 3 (SLC22A1-3). J Pharmacol Exp Ther. 308:2–9. 2004.PubMed/NCBI View Article : Google Scholar
20	Jonker JW, Wagenaar E, Van Eijl S and Schinkel AH: Deficiency in the organic cation transporters 1 and 2 (Oct1/Oct2 [Slc22a1/Slc22a2]) in mice abolishes renal secretion of organic cations. Mol Cell Biol. 23:7902–7908. 2003.PubMed/NCBI View Article : Google Scholar
21	Moll P, Ante M, Seitz A and Reda T: QuantSeq 3'mRNA sequencing for RNA quantification. Nat Methods. 12:2014.
22	Liao Y, Smyth GK and Shi W: The Subread aligner: Fast, accurate and scalable read mapping by seed-and-vote. Nucleic Acids Res. 41(e108)2013.PubMed/NCBI View Article : Google Scholar
23	Morgan M, Anders S, Lawrence M, Aboyoun P, Pagès H and Gentleman R: ShortRead: A bioconductor package for input, quality assessment and exploration of high-throughput sequence data. Bioinformatics. 25:2607–2608. 2009.PubMed/NCBI View Article : Google Scholar
24	Love MI, Huber W and Anders S: Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15(550)2014.PubMed/NCBI View Article : Google Scholar
25	Kim YO, Popov Y and Schuppan D: Optimized mouse models for liver fibrosis. Methods Mol Biol. 1559:279–296. 2017.PubMed/NCBI View Article : Google Scholar
26	Nies AT, Koepsell H, Winter S, Burk O, Klein K, Kerb R, Zanger UM, Keppler D, Schwab M and Schaeffeler E: Expression of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) is affected by genetic factors and cholestasis in human liver. Hepatology. 50:1227–1240. 2009.PubMed/NCBI View Article : Google Scholar
27	Denk GU, Soroka CJ, Mennone A, Koepsell H, Beuers U and Boyer JL: Down-regulation of the organic cation transporter 1 of rat liver in obstructive cholestasis. Hepatology. 39:1382–1389. 2004.PubMed/NCBI View Article : Google Scholar
28	Tag CG, Sauer-Lehnen S, Weiskirchen S, Borkham-Kamphorst E, Tolba RH, Tacke F and Weiskirchen R: Bile duct ligation in mice: induction of inflammatory liver injury and fibrosis by obstructive cholestasis. J Vis Exp: 52438, 2015.
29	Li WC, Ralphs KL and Tosh D: Isolation and culture of adult mouse hepatocytes. Methods Mol Biol. 633:185–196. 2010.PubMed/NCBI View Article : Google Scholar
30	Arndt P, Volk C, Gorboulev V, Budiman T, Popp C, Ulzheimer-Teuber I, Akhoundova A, Koppatz S, Bamberg E, Nagel G and Koepsell H: Interaction of cations, anions, and weak base quinine with rat renal cation transporter rOCT2 compared with rOCT1. Am J Physiol Renal Physiol. 281:F454–F468. 2001.PubMed/NCBI View Article : Google Scholar
31	Müller J, Lips KS, Metzner L, Neubert RH, Koepsell H and Brandsch M: Drug specificity and intestinal membrane localization of human organic cation transporters (OCT). Biochem Pharmacol. 70:1851–1860. 2005.PubMed/NCBI View Article : Google Scholar
32	Koepsell H: Polyspecific organic cation transporters: Their functions and interactions with drugs. Trends Pharmacol Sci. 25:375–381. 2004.PubMed/NCBI View Article : Google Scholar
33	Koepsell H, Lips K and Volk C: Polyspecific organic cation transporters: structure, function, physiological roles, and biopharmaceutical implications. Pharm Res. 24:1227–1251. 2007.PubMed/NCBI View Article : Google Scholar
34	Keller T, Elfeber M, Gorboulev V, Reiländer H and Koepsell H: Purification and functional reconstitution of the rat organic cation transporter OCT1. Biochemistry. 44:12253–12263. 2005.PubMed/NCBI View Article : Google Scholar
35	van der Velden M, Bilos A, van den Heuvel JJMW, Rijpma SR, Hurkmans EGE, Sauerwein RW, Russel FGM and Koenderink JB: Proguanil and cycloguanil are organic cation transporter and multidrug and toxin extrusion substrates. Malar J. 16(422)2017.PubMed/NCBI View Article : Google Scholar
36	Hilgendorf C, Ahlin G, Seithel A, Artursson P, Ungell AL and Karlsson J: Expression of thirty-six drug transporter genes in human intestine, liver, kidney, and organotypic cell lines. Drug Metab Dispos. 35:1333–1340. 2007.PubMed/NCBI View Article : Google Scholar
37	Hagos Y, Wegner W, Kuehne A, Floerl S, Marada VV, Burckhardt G and Henjakovic M: HNF4α induced chemosensitivity to oxaliplatin and 5-FU mediated by OCT1 and CNT3 in renal cell carcinoma. J Pharm Sci. 103:3326–3334. 2014.PubMed/NCBI View Article : Google Scholar
38	Gasser PJ and Lowry CA: Organic cation transporter 3: A cellular mechanism underlying rapid, non-genomic glucocorticoid regulation of monoaminergic neurotransmission, physiology, and behavior. Horm Behav. 104:173–182. 2018.PubMed/NCBI View Article : Google Scholar
39	Sleutels F, Tjon G, Ludwig T and Barlow DP: Imprinted silencing of Slc22a2 and Slc22a3 does not need transcriptional overlap between Igf2r and Air. EMBO J. 22:3696–3704. 2003.PubMed/NCBI View Article : Google Scholar
40	Sleutels F, Zwart R and Barlow DP: The non-coding Air RNA is required for silencing autosomal imprinted genes. Nature. 415:810–813. 2002.PubMed/NCBI View Article : Google Scholar
41	Chen L, Shu Y, Liang X, Chen EC, Yee SW, Zur AA, Li S, Xu L, Keshari KR, Lin MJ, et al: OCT1 is a high-capacity thiamine transporter that regulates hepatic steatosis and is a target of metformin. Proc Natl Acad Sci USA. 111:9983–9988. 2014.PubMed/NCBI View Article : Google Scholar
42	Chen L, Hong C, Chen EC, Yee SW, Xu L, Almof EU, Wen C, Fujii K, Johns SJ, Stryke D, et al: Genetic and epigenetic regulation of the organic cation transporter 3, SLC22A3. Pharmacogenomics J. 13:110–120. 2013.PubMed/NCBI View Article : Google Scholar
43	Nagano T, Mitchell JA, Sanz LA, Pauler FM, Ferguson-Smith AC, Feil R and Fraser P: The Air noncoding RNA epigenetically silences transcription by targeting G9a to chromatin. Science. 322:1717–1720. 2008.PubMed/NCBI View Article : Google Scholar